MM.02.026 Genetic Testing for Mental Health Conditions - 7/15
ثبت نشده
چکیده
Psychiatric disorders cover a wide range of clinical phenotypes and are generally classified by symptomatology in systems such as the classification outlined in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). In addition to counseling and other forms of behavioral treatment, treatment commonly involves 1 or more psychotropic medications that are aimed at alleviating symptoms of the disorder. Although there are a wide variety of effective medications, treatment of psychiatric disease is characterized by relatively high rates of inadequate response. This often necessitates numerous trials of individual agents and combinations of medications to achieve optimal response.
منابع مشابه
Medical Policy Policy Title Genetic Testing for Mental Health Conditions
Genetic testing panels for mental health disorders, including but not limited to the Genecept Assay, STA2R test, the GeneSight Psychotropic panel, the Proove Narcotic Risk assay and the Mental Health DNA Insight Panel, are considered investigational for all indications. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.
متن کاملGenetic Testing and Neuroimaging: Trading off Benefit and Risk for Youth with Mental Illness.
According to the World Health Organization, mental illness is one of the leading causes of disability worldwide. The first onset of mental illness usually occurs during childhood or adolescence. Neuroimaging and genetic testing have been invaluable in research on behavioral and intentional disorders, particularly with their potential to lead to improved diagnostic and predictive capabilities an...
متن کاملGuidelines for genetic testing of healthy children.
Recent international efforts to sequence the human genome have greatly enhanced our ability to test definitively for many genetic conditions. For many, this has been welcome, allowing the diagnosis of disorders that have been previously only suspected. This has also led to the advent of the ‘unpatient’ [1], where there is an increasing ability to test healthy individuals for genetic conditions ...
متن کاملHyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia
Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (...
متن کاملThe effectiveness of specialist roles in mental health metabolic monitoring: a retrospective cross-sectional comparison study
BACKGROUND People with serious mental illness (SMI) exhibit a high prevalence of cardiovascular diseases. Mental health services have a responsibility to address poor physical health in their consumers. One way of doing this is to conduct metabolic monitoring (MM) of risk factors for cardiovascular diseases. This study compares two models of MM among consumers with SMI and describes referral pa...
متن کامل